v.7.8.0 Search Results


uv vis nir spectrophotometer model v 670 jasco tokyo japan  (JASCO Inc)
99
JASCO Inc uv vis nir spectrophotometer model v 670 jasco tokyo japan
Uv Vis Nir Spectrophotometer Model V 670 Jasco Tokyo Japan, supplied by JASCO Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/uv vis nir spectrophotometer model v 670 jasco tokyo japan/product/JASCO Inc
Average 99 stars, based on 1 article reviews
uv vis nir spectrophotometer model v 670 jasco tokyo japan - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
uv vis nir spectrometer  (JASCO Inc)
99
JASCO Inc uv vis nir spectrometer
Uv Vis Nir Spectrometer, supplied by JASCO Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/uv vis nir spectrometer/product/JASCO Inc
Average 99 stars, based on 1 article reviews
uv vis nir spectrometer - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
md 2010 plus uv vis photodiode array detector  (JASCO Inc)
97
JASCO Inc md 2010 plus uv vis photodiode array detector
Md 2010 Plus Uv Vis Photodiode Array Detector, supplied by JASCO Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/md 2010 plus uv vis photodiode array detector/product/JASCO Inc
Average 97 stars, based on 1 article reviews
md 2010 plus uv vis photodiode array detector - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
software v. 7.8.0.0  (MetaMorph Inc)
90
MetaMorph Inc software v. 7.8.0.0
Software V. 7.8.0.0, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/software v. 7.8.0.0/product/MetaMorph Inc
Average 90 stars, based on 1 article reviews
software v. 7.8.0.0 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cd4 (v780  (Becton Dickinson)
90
Becton Dickinson cd4 (v780
Landscape of T cell differentiation, activation state, inhibitory and stimulatory checkpoint receptors of tumor infiltrating T cells in HCC, PDA and CCA. (A) Percentage of <t>CD4+</t> T cells and CD8+ T cells in CD3+ T cells in HCC (n=11), PDA (n=20) and CCA (n=5) patients. (B, C) Boxplots showing frequency of T cell differentiation markers and activation markers in CD8+ T cells (B) and CD4+ T cells (C) in HCC, PDA and CCA patients. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. Kruskal-Wallis test. (D) Inhibitory and stimulatory checkpoint receptors frequency of CD8+ T cell. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05; ** p < 0.01; Kruskal-Wallis test. (E) Inhibitory and stimulatory checkpoint receptors frequency of CD4+ T cell. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05; ** p < 0.01; Kruskal-Wallis test.
Cd4 (V780, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd4 (v780/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd4 (v780 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Landscape of T cell differentiation, activation state, inhibitory and stimulatory checkpoint receptors of tumor infiltrating T cells in HCC, PDA and CCA. (A) Percentage of CD4+ T cells and CD8+ T cells in CD3+ T cells in HCC (n=11), PDA (n=20) and CCA (n=5) patients. (B, C) Boxplots showing frequency of T cell differentiation markers and activation markers in CD8+ T cells (B) and CD4+ T cells (C) in HCC, PDA and CCA patients. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. Kruskal-Wallis test. (D) Inhibitory and stimulatory checkpoint receptors frequency of CD8+ T cell. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05; ** p < 0.01; Kruskal-Wallis test. (E) Inhibitory and stimulatory checkpoint receptors frequency of CD4+ T cell. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05; ** p < 0.01; Kruskal-Wallis test.

Journal: Frontiers in Immunology

Article Title: Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies

doi: 10.3389/fimmu.2023.1067352

Figure Lengend Snippet: Landscape of T cell differentiation, activation state, inhibitory and stimulatory checkpoint receptors of tumor infiltrating T cells in HCC, PDA and CCA. (A) Percentage of CD4+ T cells and CD8+ T cells in CD3+ T cells in HCC (n=11), PDA (n=20) and CCA (n=5) patients. (B, C) Boxplots showing frequency of T cell differentiation markers and activation markers in CD8+ T cells (B) and CD4+ T cells (C) in HCC, PDA and CCA patients. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. Kruskal-Wallis test. (D) Inhibitory and stimulatory checkpoint receptors frequency of CD8+ T cell. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05; ** p < 0.01; Kruskal-Wallis test. (E) Inhibitory and stimulatory checkpoint receptors frequency of CD4+ T cell. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05; ** p < 0.01; Kruskal-Wallis test.

Article Snippet: A 25 parameter antibody panel was developed using ColorWheel software ( ) to include T cell markers of differentiation, activation, trafficking, phenotype, co-inhibitory and co-stimulatory checkpoint molecules CD186 (B515), CD137 (B610), CD244 (B710), CD57 (B780), CD45RO (R670), HLA-DR (R710), GITR (R780), CD278 (V420), CD95 (V475), CD103 (V610), CD183 (V670), CD134 (V710), CD69 (V740), CD4 (V780), CCR7 (U380), Viability dye (U450), CD3 (U515), CD25 (U585), CD366 (U670), PD-1 (U740), CD8 (U820), TIGIT (G575), CD272 (G610), CD127 (G670) and CD152 (G780) (BD Biosciences) ( ).

Techniques: Cell Differentiation, Activation Assay

Distinct CD4+ T cell phenotypes in liver and pancreatic cancers. (A) tSNE projection of CD4+ T cells showing 16 manual-gated clusters identified from HCC (n=11), PDA (n=20) and CCA (n=5) patients. Significantly enriched clusters in HCC (C2, C6) and PDA (C3, C12, C13) are labeled. (B) Boxplots showing percentage of HCC-enriched clusters C2 and C6 in CD4+ T cells from tSNE (A) . Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. **p < 0.01, Kruskal-Wallis test. (C) Histograms show the individual marker expression of CD4+ T cell clusters enriched in HCC, C2 (red) and C6 (blue). (D) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 16 clusters of CD4+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (E) Combinatoric frequency analysis of CD4+ marker combinations (TerraFlow-Methods) most frequent in HCC. Boxplots showing representative phenotypes of CD4+ T cells that are significantly higher in HCC compared to PDA. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05, **p < 0.01, Kruskal-Wallis test. (F) Boxplots showing percentage of PDA-enriched clusters C3, C12 and C13 in CD4+ T cells from tSNE (A) . Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05,**p < 0.01, Kruskal-Wallis test. (G) Histograms showing the individual marker expression CD4+ T cell clusters enriched in PDA of C3 (red), C12 (green) and C13 (blue). (H) Combinatoric frequency analysis of CD4+ marker combinations (TerraFlow-Methods) most frequent in PDA. Boxplots showing representative phenotypes of CD4+ T cell that are significantly higher in PDA compared to HCC. Representative statistically and biologically significant phenotypes are shown. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. **p < 0.01, Kruskal-Wallis test.

Journal: Frontiers in Immunology

Article Title: Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies

doi: 10.3389/fimmu.2023.1067352

Figure Lengend Snippet: Distinct CD4+ T cell phenotypes in liver and pancreatic cancers. (A) tSNE projection of CD4+ T cells showing 16 manual-gated clusters identified from HCC (n=11), PDA (n=20) and CCA (n=5) patients. Significantly enriched clusters in HCC (C2, C6) and PDA (C3, C12, C13) are labeled. (B) Boxplots showing percentage of HCC-enriched clusters C2 and C6 in CD4+ T cells from tSNE (A) . Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. **p < 0.01, Kruskal-Wallis test. (C) Histograms show the individual marker expression of CD4+ T cell clusters enriched in HCC, C2 (red) and C6 (blue). (D) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 16 clusters of CD4+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (E) Combinatoric frequency analysis of CD4+ marker combinations (TerraFlow-Methods) most frequent in HCC. Boxplots showing representative phenotypes of CD4+ T cells that are significantly higher in HCC compared to PDA. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05, **p < 0.01, Kruskal-Wallis test. (F) Boxplots showing percentage of PDA-enriched clusters C3, C12 and C13 in CD4+ T cells from tSNE (A) . Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05,**p < 0.01, Kruskal-Wallis test. (G) Histograms showing the individual marker expression CD4+ T cell clusters enriched in PDA of C3 (red), C12 (green) and C13 (blue). (H) Combinatoric frequency analysis of CD4+ marker combinations (TerraFlow-Methods) most frequent in PDA. Boxplots showing representative phenotypes of CD4+ T cell that are significantly higher in PDA compared to HCC. Representative statistically and biologically significant phenotypes are shown. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. **p < 0.01, Kruskal-Wallis test.

Article Snippet: A 25 parameter antibody panel was developed using ColorWheel software ( ) to include T cell markers of differentiation, activation, trafficking, phenotype, co-inhibitory and co-stimulatory checkpoint molecules CD186 (B515), CD137 (B610), CD244 (B710), CD57 (B780), CD45RO (R670), HLA-DR (R710), GITR (R780), CD278 (V420), CD95 (V475), CD103 (V610), CD183 (V670), CD134 (V710), CD69 (V740), CD4 (V780), CCR7 (U380), Viability dye (U450), CD3 (U515), CD25 (U585), CD366 (U670), PD-1 (U740), CD8 (U820), TIGIT (G575), CD272 (G610), CD127 (G670) and CD152 (G780) (BD Biosciences) ( ).

Techniques: Labeling, Marker, Expressing, Activation Assay

HCC disease stage and effect on T cell phenotypes. (A) tSNE projection of CD8+ T cells showing 6 manual-gated clusters identified from early stage (n=6) and late stage (n=4) HCC patients. Significantly enriched clusters in early stage (C1, C4) and late stage (C6) HCC patients are labeled. (B) Boxplots showing percentage of early stage-enriched CD8+ T cell clusters C1 and C4 and late stage-enriched cluster C6 in HCC patients. *p < 0.05, Kruskal-Wallis test. (C) Histograms showing the individual marker expression of early stage-enriched CD8+ T cell clusters C1 (red), C4 (green), and late stage-enriched cluster C6 (blue) in HCC patients. (D) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 6 clusters of CD8+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (E) tSNE projection of CD4+ T cells showing 7 manual-gated clusters identified from early stage (n=7) and late stage (n=5) HCC patients. Significantly enriched clusters in early stage (C1) and late stage (C7) HCC patients are labeled. (F) Boxplots showing percentage of early stage HCC enriched CD4+ T cell cluster C1 and late stage HCC enriched cluster C7. *p < 0.05, Kruskal-Wallis test. (G) Histograms showing individual marker expression of early stage HCC enriched CD4+ T cell cluster C1 (red) and late stage HCC enriched cluster C7 (blue). (H) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 7 clusters of CD4+ T cells is shown in heatmap which is arranged based on the expression level of CD103.

Journal: Frontiers in Immunology

Article Title: Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies

doi: 10.3389/fimmu.2023.1067352

Figure Lengend Snippet: HCC disease stage and effect on T cell phenotypes. (A) tSNE projection of CD8+ T cells showing 6 manual-gated clusters identified from early stage (n=6) and late stage (n=4) HCC patients. Significantly enriched clusters in early stage (C1, C4) and late stage (C6) HCC patients are labeled. (B) Boxplots showing percentage of early stage-enriched CD8+ T cell clusters C1 and C4 and late stage-enriched cluster C6 in HCC patients. *p < 0.05, Kruskal-Wallis test. (C) Histograms showing the individual marker expression of early stage-enriched CD8+ T cell clusters C1 (red), C4 (green), and late stage-enriched cluster C6 (blue) in HCC patients. (D) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 6 clusters of CD8+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (E) tSNE projection of CD4+ T cells showing 7 manual-gated clusters identified from early stage (n=7) and late stage (n=5) HCC patients. Significantly enriched clusters in early stage (C1) and late stage (C7) HCC patients are labeled. (F) Boxplots showing percentage of early stage HCC enriched CD4+ T cell cluster C1 and late stage HCC enriched cluster C7. *p < 0.05, Kruskal-Wallis test. (G) Histograms showing individual marker expression of early stage HCC enriched CD4+ T cell cluster C1 (red) and late stage HCC enriched cluster C7 (blue). (H) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 7 clusters of CD4+ T cells is shown in heatmap which is arranged based on the expression level of CD103.

Article Snippet: A 25 parameter antibody panel was developed using ColorWheel software ( ) to include T cell markers of differentiation, activation, trafficking, phenotype, co-inhibitory and co-stimulatory checkpoint molecules CD186 (B515), CD137 (B610), CD244 (B710), CD57 (B780), CD45RO (R670), HLA-DR (R710), GITR (R780), CD278 (V420), CD95 (V475), CD103 (V610), CD183 (V670), CD134 (V710), CD69 (V740), CD4 (V780), CCR7 (U380), Viability dye (U450), CD3 (U515), CD25 (U585), CD366 (U670), PD-1 (U740), CD8 (U820), TIGIT (G575), CD272 (G610), CD127 (G670) and CD152 (G780) (BD Biosciences) ( ).

Techniques: Labeling, Marker, Expressing, Activation Assay

PDA disease stage and effect on T cell phenotypes (A) tSNE projection of CD8+ T cells showing 16 manual-gated clusters identified from early stage (n=11) and late stage (n=4) PDA patients. Significantly enriched clusters in early stage (C6, C8, C10) and late stage (C12) PDA patients are labeled. (B) Boxplots showing percentage of early stage-enriched CD8+ T cell clusters and late stage-enriched clusters. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05, Kruskal-Wallis test. (C) Histograms showing individual marker expression of early stage-enriched CD8+ T cell clusters in C6 (orange), C8 (red), C10 (purple) and late stage-enriched cluster C12 (blue). (D) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 16 clusters of CD8+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (E) tSNE projection of CD4+ T cells showing 12 manual-gated clusters identified from early stage (n=13) and late stage (n=5) PDA patients. Significantly enriched clusters in early stage (C6) and late stage (C10) PDA patients are labeled. (F) Boxplots showing percentage of early stage-enriched CD4+ T cell cluster C6 and late stage-enriched cluster C10. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05, Kruskal-Wallis test. (G) Histograms showing the individual marker expression of early stage-enriched CD4+ T cell clusters C6 (red) and late stage-enriched clusters C10 (blue). (H) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 12 clusters of CD4+ T cells is shown in heatmap which is arranged based on the expression level of CD103.

Journal: Frontiers in Immunology

Article Title: Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies

doi: 10.3389/fimmu.2023.1067352

Figure Lengend Snippet: PDA disease stage and effect on T cell phenotypes (A) tSNE projection of CD8+ T cells showing 16 manual-gated clusters identified from early stage (n=11) and late stage (n=4) PDA patients. Significantly enriched clusters in early stage (C6, C8, C10) and late stage (C12) PDA patients are labeled. (B) Boxplots showing percentage of early stage-enriched CD8+ T cell clusters and late stage-enriched clusters. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05, Kruskal-Wallis test. (C) Histograms showing individual marker expression of early stage-enriched CD8+ T cell clusters in C6 (orange), C8 (red), C10 (purple) and late stage-enriched cluster C12 (blue). (D) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 16 clusters of CD8+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (E) tSNE projection of CD4+ T cells showing 12 manual-gated clusters identified from early stage (n=13) and late stage (n=5) PDA patients. Significantly enriched clusters in early stage (C6) and late stage (C10) PDA patients are labeled. (F) Boxplots showing percentage of early stage-enriched CD4+ T cell cluster C6 and late stage-enriched cluster C10. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p < 0.05, Kruskal-Wallis test. (G) Histograms showing the individual marker expression of early stage-enriched CD4+ T cell clusters C6 (red) and late stage-enriched clusters C10 (blue). (H) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 12 clusters of CD4+ T cells is shown in heatmap which is arranged based on the expression level of CD103.

Article Snippet: A 25 parameter antibody panel was developed using ColorWheel software ( ) to include T cell markers of differentiation, activation, trafficking, phenotype, co-inhibitory and co-stimulatory checkpoint molecules CD186 (B515), CD137 (B610), CD244 (B710), CD57 (B780), CD45RO (R670), HLA-DR (R710), GITR (R780), CD278 (V420), CD95 (V475), CD103 (V610), CD183 (V670), CD134 (V710), CD69 (V740), CD4 (V780), CCR7 (U380), Viability dye (U450), CD3 (U515), CD25 (U585), CD366 (U670), PD-1 (U740), CD8 (U820), TIGIT (G575), CD272 (G610), CD127 (G670) and CD152 (G780) (BD Biosciences) ( ).

Techniques: Labeling, Marker, Expressing, Activation Assay

Effect of neoadjuvant chemotherapy on T cell phenotypes in PDA patients (A) tSNE projection of CD8+ T cells showing 30 FlowSOM clusters identified from PDA patients treated with (n=6) or without (n=8) neoadjuvant chemotherapy. Significantly enriched clusters in neoadjuvant treatment group (C5, C9, C16) and no treatment group (C1) are labeled. (B) Boxplots showing phenotypes of CD8+ T cell clusters enriched following neoadjuvant chemotherapy. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p<0.05, **p < 0.01, Kruskal-Wallis test. (C) Histograms show the single marker phenotypes of CD8+ T cell clusters C5 (red), C9 (purple) and C16 (orange) enriched in PDA patients treated with neoadjuvant chemotherapy and cluster C1 (blue) enriched in PDA patients without neoadjuvant treatment. (D) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 30 clusters of CD8+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (E) tSNE projection of CD4+ T cells showing 30 FlowSOM clusters identified from PDA patients treated with (n=7) or without (n=9) neoadjuvant chemotherapy. Significantly enriched cluster C15 in neoajuvant treatment group is labeled. (F) Boxplot shows cluster C15 (p<0.05) increased in CD4+ T cells from PDA patients treated with neoadjuvant. (G) Histograms show the phenotype of C15 (red) in CD4+ T cells from PDA patients treated with neoadjuvant chemotherapy. (H) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 30 clusters of CD4+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (I, J) . Combinatoric frequency analysis of CD4+ marker combinations in response to neoadjuvant chemotherapy (TerraFlow-Methods). Boxplots showing representative phenotypes of CD4+ T cells that are significantly higher in treatment-naïve PDA patients (I) or patients receiving neoadjuvant chemotherapy (J) .

Journal: Frontiers in Immunology

Article Title: Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies

doi: 10.3389/fimmu.2023.1067352

Figure Lengend Snippet: Effect of neoadjuvant chemotherapy on T cell phenotypes in PDA patients (A) tSNE projection of CD8+ T cells showing 30 FlowSOM clusters identified from PDA patients treated with (n=6) or without (n=8) neoadjuvant chemotherapy. Significantly enriched clusters in neoadjuvant treatment group (C5, C9, C16) and no treatment group (C1) are labeled. (B) Boxplots showing phenotypes of CD8+ T cell clusters enriched following neoadjuvant chemotherapy. Box middle lines, median; box limits upper and lower quartiles; box whiskers, 1.5x the interquartile range. *p<0.05, **p < 0.01, Kruskal-Wallis test. (C) Histograms show the single marker phenotypes of CD8+ T cell clusters C5 (red), C9 (purple) and C16 (orange) enriched in PDA patients treated with neoadjuvant chemotherapy and cluster C1 (blue) enriched in PDA patients without neoadjuvant treatment. (D) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 30 clusters of CD8+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (E) tSNE projection of CD4+ T cells showing 30 FlowSOM clusters identified from PDA patients treated with (n=7) or without (n=9) neoadjuvant chemotherapy. Significantly enriched cluster C15 in neoajuvant treatment group is labeled. (F) Boxplot shows cluster C15 (p<0.05) increased in CD4+ T cells from PDA patients treated with neoadjuvant. (G) Histograms show the phenotype of C15 (red) in CD4+ T cells from PDA patients treated with neoadjuvant chemotherapy. (H) Expression of TRM-related markers, co-inhibitory/senescent markers, co-stimulatory markers and memory/activation markers in 30 clusters of CD4+ T cells is shown in heatmap which is arranged based on the expression level of CD103. (I, J) . Combinatoric frequency analysis of CD4+ marker combinations in response to neoadjuvant chemotherapy (TerraFlow-Methods). Boxplots showing representative phenotypes of CD4+ T cells that are significantly higher in treatment-naïve PDA patients (I) or patients receiving neoadjuvant chemotherapy (J) .

Article Snippet: A 25 parameter antibody panel was developed using ColorWheel software ( ) to include T cell markers of differentiation, activation, trafficking, phenotype, co-inhibitory and co-stimulatory checkpoint molecules CD186 (B515), CD137 (B610), CD244 (B710), CD57 (B780), CD45RO (R670), HLA-DR (R710), GITR (R780), CD278 (V420), CD95 (V475), CD103 (V610), CD183 (V670), CD134 (V710), CD69 (V740), CD4 (V780), CCR7 (U380), Viability dye (U450), CD3 (U515), CD25 (U585), CD366 (U670), PD-1 (U740), CD8 (U820), TIGIT (G575), CD272 (G610), CD127 (G670) and CD152 (G780) (BD Biosciences) ( ).

Techniques: Labeling, Marker, Expressing, Activation Assay